Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on Nov 17, 2014 10:42am

202 Views

Post# 23135695

RE:ANOTHER INTERESTING POST BY F6 ON THE OTHER BOARD

If I am not mistaken, I think this one has been around for a long time (many years - this is just the write up). I recall hearing that it has issues in terms of "drugability" so it is not a viable competitor to RVX-208.

This all second hand, so please confirm for yourself....

If someone with a scientific background can confirm, please do so.

Bullboard Posts

Dynamic Funds Launches new ETF series on the TSX